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Summary: Bone metastases in cancer of the prostate are diagnosed routinely by isotope bone scintigraphy and the
measurement of alkaline phosphatase in serum and the calcium excretion in urine. The specificity of these examina-
tions is in general not satisfactory. We therefore investigated the diagnostic value of five new markers of bone
formation and bone resorption for the detection of the metastatic process. In a group of 43 patients with carcinoma
of the prostate the carboxyterminal propeptide, the carboxyterminal cross-linked telopeptide, the aminoterminal
cross-linked telopeptide, and the deoxypyridinoline cross-links of type 1 collagen were measured as well as the
specific bone alkaline phosphatase isoenzyme. A group of 34 patients with benign prostatic hyperplasia served as
a control. A receiver-operating characteristic analysis was performed. It appeared that the sensitivity of carboxyter-
minal cross-linked telopeptide of type I collagen was the greatest (89%), while the best specificity was obtained for
the deoxypyridinoline cross-links assay (92%). The diagnostic values of the new markers were generally comparable
with those of alkaline phosphatase although carboxyterminal cross-linked telopeptide of type I collagen yielded
better results, but those with carboxyterminal propeptide of type I procollagen were less satisfactory. Calcium
excretion in urine had no added value at all.
Introduction
Metastatic bone disease is one of the most dominant
extensions in adult patients with malignancy. In partic-
ular, patients with carcinoma of the prostate are at
risk for metastatic bone involvement. The median sur-
vival is about 2.5 years from the time of diagnosis of
bone metastases and 80% of patients who die from
prostate cancer have bone metastases (1). Until now
the diagnosis of bone metastases has mainly relied on
isotope bone scintigraphy. Although bone scintigraphy
has a high sensitivity, the specificity appears to be
low and it is difficult to quantitate routinely the uptake
of isotope (2).
Collagen type I is the most abundant protein in bone, so
it is not surprising that the use of biochemical collagen
markers has been investigated in metastatic bone dis-
ease. Several authors have recently reported not only
increased production of collagen formation markers, but
also of collagen resorption markers in patients with met-
astatic bone disease (3—7). In general it appears from
these studies that the specificity of the collagen markers
is rather poor, reducing their diagnostic value for detec-
tion of the metastatic process in bone. However, the pa-
tient groups in these studies were very heterogeneous
with respect to their primary malignant disease and only
very few patients with carcinoma of the prostate were
included. This might be an explanation for the low over-
all specificity of the collagen markers studied.
In a well-defined group of patients with metastatic
prostate cancer it was recently demonstrated that the
levels of carboxyterminal cross-linked telopeptide of
type I collagen and of carboxyterminal propeptide of
type I collagen were considerably higher than the nor-
mal reference values and that carboxyterminal cross-
linked telopeptide of type I collagen did yield some
information about the prognosis of the disease (8).
This study did not contain any patients who had pros-
tate cancer without bone metastases and there was no
control group, so no data were presented on the speci-
ficity or sensitivity of the markers studied. Another
recent study (9) showed elevations of collagen markers
in patients with prostatic bone metastases compared
with patients without them. However, a considerable
overlap between the results of the two groups caused
a low sensitivity.
In order to establish the diagnostic value of some bio-
chemical bone markers for the detection of bone meta-
stases in prostate cancer we performed a receiver-operat-
ing characteristic analysis for some markers of bone for-
mation and of bone resorption in two groups of patients
with prostate cancer (with or without bone metastases).
A group of patients with benign prostatic hyperplasia
served as a control group. In this study, the bone forma-
tion markers alkaline phosphastase, specific bone alka-
line phosphatase and carboxyterminal propeptide of ty-
pe I procollagen were measured together with the bone
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resorption markers carboxyterminal cross-linked telo-
peptide of type I collagen, the urinary calcium excretion,
deoxypyridinoline cross-links and the amino terminal
telopeptide of type I collagen.
Patients and Methods
In total, 77 patients gave informed consent for this study. Thirty-
four patients had a clinically diagnosed benign prostatic hyperpla-
sia and 43 patients had cancer of the prostate, confirmed histologi-
cally after a biopsy or radical prostatectomy. All patients with can-
cer underwent 99-m-technetium bone scintigraphy and were, ac-
cording to the results of this examination, divided into two groups
PC- and PC+, without and with bone metastases. Blood samples
were taken in the morning between 8.30 a. m. and 9.30 a. m. Blood
was collected in plain plastic tubes, allowed to clot and serum was
separated from erythrocytes by centrifugation at 4 °C, for 10 min
at 1500g. The samples were divided for the different determin-
ations and frozen at —70 °C prior to assay. Urine samples for the
determination of deoxypyridinoline cross-links, aminoterminal tel-
opeptide of type I collagen and calcium excretions were obtained
from an overnight urine portion including the early morning por-
tion. After division into aliquots, the urine samples were also fro-
zen at —70 °C before assay. Urinary concentrations were expressed
relative to the urinary creatinine levels.
Alkaline phosphatase
Activity of total alkaline phosphatase in serum was measured at
37 °C, following the recommendations of the IFCC, using a Cobas
Integra Analyzer (Roche, Switzerland).
Bone alkaline phosphatase
Bone alkaline phosphatase in serum was determined by means of
an enzyme immuno-assay according to the manufacturer's instruc-
tions (Alkphase-B, Metra Biosystems, Palo Alto, USA).
Carboxyterminal propeptide of type I procollagen/
carboxyterminal cross-linked telopeptide of type I
collagen
The concentrations of carboxyterminal propeptide of type I procol-
lagen and carboxyterminal cross-linked telopeptide of type I colla-
gen in serum were assessed by commercially available radio-im-
muno-assays according to the manufacturer's instructions (Orion
Diagnostica, Finland).
Deoxypyridinoline cross-links
Urinary concentration of free deoxypyridinoline was determined
by a competitive enzyme immuno-assay (Pyrilinks-D, Metra Bio-
systems, Palo Alto, USA) according to the manufacturer's instruc-
tions.
Aminoterminal telopeptide of type I collagen
Urinary concentration of the aminoterminal telopeptide was deter-
mined by ELISA (Osteomark) according to the manufacturer's in-
structions (Ostex International, Seattle, WA, USA).
Calcium and creatinine in urine
Urinary calcium concentration was determined by means of atomic
absorption spectrophotometry (Perkin Elmer 2380) and urinary cre-
atinine was determined by the alkaline picrate method using a Co-
bas Integra Analyzer (Roche, Switzerland).
Prostate-specific antigen
The level of prostate-specific antigen in serum was determined
with a fluoro-immunometric assay on an AutoDelfia automatic im-
muno-assay system according to the manufacturer's instructions
(Wallac OY, Turku, Finland).
Statistical analyses
All analytes measured are presented as medians and ranges. The
significance of differences between groups of patients was as-
sessed using the Mann-Whitney U-test. The probability of falsely
declaring one or more differences to be significant caused by
multiple comparisons between groups was eliminated by apply-
ing the principle of Bonferroni's inequality (10). This means that
the significance level was adjusted for the number (n = 3) of
comparisons between the patient groups. The different quantities
were correlated with each other with the Spearman rank correla-
tion test. The sensitivity and specificity of the analytes for pre-
dicting metastatic bone involvement (according to scintigraphic
criteria) were calculated for several arbitrarily chosen cutoff
levels. Receiver operating-characteristic curves were constructed
by plotting the sensitivity against 100 minus the specificity. The
resulting areas under the receiver operating-characteristic curves
were used as a measure for comparing the diagnostic values of
the different analytes.
Results
Table 1 shows some characteristics of the patient groups.
The group of patients with benign prostate hyperplasia
appeared to have normal prostate-specific antigen values
(< 10 μ^Ι). On the other hand, practically all patients
with carcinoma of the prostate appeared to have elevated
prostate-specific antigen values at the time of diagnosis
of the carcinoma. It can be concluded that the diagnostic
value of the prostate-specific antigen level in serum for
the discrimination between benign prostatic hyperplasia
and prostate carcinoma was associated with almost
100% specificity and 100% sensitivity. According to the
bone scintigraphic data, the carcinoma patients were
subdivided into a group with, and a group without, bone
metastases. Although the prostate-specific antigen val-
ues of these two groups showed some overlap, statistic-
ally significantly different median values were measured
for the two groups. The median values for the bone
markers measured in the three different patient groups
are shown in table 2. All analytes yielded values above
the upper reference limits in the group of prostate carci-
noma patients with bone metastases. These values, com-
pared with those from the group of prostate carcinoma
patients without bone involvement, were all statistically
significantly raised, except for the urinary calcium
excretion. In the two patient groups with benign pros-
tatic hyperplasia and PC— all markers were within the
normal reference interval except for the urinary calcium
excretion results.
Table 3 shows the Spearman rank correlation coeffi-
cients of the bone markers in patients with prostatic hy-
perplasia and prostatic cancer with or without bone me-
tastases. It appeared that the bone formation markers
and the bone resorption markers were positively signifi-
cantly correlated. The urinary calcium excretion results
did not correlate at all with the other quantities. In order
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to compare the diagnostic value of the different bone
markers for the discrimination between prostatic carci-
noma patients with and without bone metastases, the in-
dividual receiver operating-characteristic curves for
each analyte are shown in figure 1. The areas under the
curves can be considered as a measure of the diagnostic
value of the particular bone marker. These diagnostic
values are shown in table 4. Based on the receiver oper-
ating-characteristic analysis, cutoff levels for the diagno-
sis of bone metastasis were also established. These cut-
off levels were associated with the maximal diagnostic
efficiency (sum of sensitivity and specificity) and are
also shown in table 4.
Discussion
In the present study, seven biochemical markers of
bone metabolism were studied in a benign prostatic
hyperplasia control group and in prostatic cancer pa-
tients with or without scintigraphic evidence of bone
metastases. A biochemical marker with the ability to
discriminate between patients with and without meta-
Tab. 1 Characteristics of the patient group with prostate disease.
Age and prostate-specific antigen values are given in medians and
ranges. Prostate-specific antigen was measured at the time of diag-
























* PC- versus PC + : p < 0.001 ** Benign prostatic hyperplasia versus PC-: p < 0.001
Tab. 2 Determination of markers of bone turnover in patients with prostate disease. Values are given
































































* PC+ versus PC- or benign prostatic hyperplasia: ρ < 0.001
Tab. 3 Spearman rank correlation coefficients for the correlation
between bone resorption and bone formation markers in patients
with prostate disease. All correlation coefficients differed signifi-






























Fig. 1 Receiver-operating characteristic analysis of bone forma-
tion markers (fig. la) and bone resorption markers (fig. Ib) for the
detection of bone metastases in a group of prostate carcinoma pa-
tients with and without scintigraphic evidence for bone metastases.
Fig. la: alkaline phosphatase D; bone alkaline phosphatase o; car-
boxyterminal propeptide Δ.
Fig. Ib: Calcium excretion in urine V; urinary aminoterminal telo-
peptide excretion Δ; urinary deoxypyridinoline excretion D; car-
boxyterminal telopeptide o.
static bone involvement would be important for early
diagnosis and treatment of advanced cancer of the
prostate. The results show that the bone metastatic
process in prostate cancer causes a significant rise in
biochemical bone formation markers as well as bone
resorption markers (tab. 2) and that these markers are
mutually correlated (tab. 3). This is in line with the
observations that bone involvement in prostatic cancer
is mostly caused by increased numbers of active osteo-
blasts (11) and that the osteoclastic response may be
due to increased parathyroid hormone secretion as a
consequence of the higher calcium demand in the
osteoblastic metastasis (12, 13).
Although not a marker of the primary osteoblastic pro-
cess, the collagen resorption marker carboxyterminal
cross-linked telopeptide of type I collagen shows the
highest diagnostic value (tab. 4). A specificity of 88%
together with a sensitivity of 89% make this analyte
slightly more suitable for the diagnosis of bone metasta-
ses, compared for instance with the routinely employed
determination of total alkaline phosphatase. Recently, a
high specificity of carboxyterminal cross-linked telopep-
tide of type I collagen for the diagnosis of bone metasta-
ses was also reported in a group of prostate cancer pa-
tients (9) and in a group of miscellaneous cancer patients
(7) but this was associated with a very low sensitivity.
This could be caused by the fact that in these studies no
receiver operating-characteristic analysis to determine
the optimal cutoff level was performed. In a group of
heterogeneous cancer patients with bone metastases it
has recently been reported that the urinary excretion of
collagen deoxypyridinoline cross-links is very promis-
ing for the detection or follow up of metastatic bone
involvement (3—5). In these studies the carboxyterminal
cross-linked telopeptide of type I collagen resorption
marker was not taken into account and patients with
metastatic prostate carcinoma were not included in two
of the studies (3, 4) and only in a very small number (7
patients) in the third study (5). The present results also
Tab. 4 Diagnostic value, cutoff level, sensitivity and specificity of biochemical bone resorption and
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* area under the receiver operating-characteristic curve
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confirm the good diagnostic value of deoxypyridinoline
cross-links for the detection of bone metastases, and it
can be concluded that it shows even a better specificity
compared with carboxyterminal cross-linked telopeptide
of type I collagen or aminoterminal telopeptide of type I
collagen. In a recent report a receiver operating-charac-
teristic analysis was performed for the efficacy of uri-
nary pyridinium cross-links for the detection of neoplas-
tic bone disease (6). It was found that the cross-link
excretion had a low specificity (ca. 40%), reducing its
diagnostic value. However, this result is not comparable
with our data on diagnostic values, probably because
there were 98 patients with different kinds of bone neo-
plasia and with heterogeneous primary diseases studied
(6).
In one of these studies on heterogeneous cancer patients
(3) it was also reported that the measurement of amino-
terminal telopeptide of type I collagen was the most suit-
able assay for predicting the presence of bone metastases
although the sensitivity was only about 40%. In the pre-
sent study we found a much higher sensitivity for the
aminoterminal telopeptide of type I collagen assay re-
sulting in a good diagnostic value for the presence of
bone metastases, comparable with the results of urinary
cross-link excretion tests.
We conclude that the three bone markers carboxytermi-
nal cross-linked telopeptide of type I collagen, deoxy-
pyridinoline cross-links and aminoterminal telopeptide
of type I collagen are suitable for the assessment of bone
metastases and have a comparable diagnostic value for
the assessment of advanced bone resorption. It is clear
from our results that the determination of urinary
calcium excretion has no added value at all. Bone for-
mation was evaluated by measuring the alkaline phos-
phatase enzyme from the osteoblast and the carboxy ter-
minal propeptide from type I procollagen. In the present
group of patients, alkaline phosphatase and the bone iso-
enzyme (bone alkaline phosphatase) perform equally
well with respect to the diagnosis of advanced prostate
carcinoma. Surprisingly, carboxyterminal propeptide of
type I procollagen was neither more sensitive nor spe-
cific than alkaline phosphatase and bone alkaline phos-
phatase. This is in line with the results ofKylmälä et al.
(8), who concluded that the synthesis of a large protein
such as type I collagen was possibly disturbed or re-
tarded by cancer cells in advanced malignant disease. It
is known that prostate-specific antigen in serum has a
high diagnostic value in the early diagnosis of prostate
cancer and in the present study it was almost completely
possible to differentiate between patients with or without
carcinoma of the prostate on the basis of prostate-spe-
cific antigen measurements, although the diagnostic
value of prostate-specific antigen for detecting bone me-
tastases was limited to 0.87 (receiver operating-charac-
teristic curve not shown). This is also in accordance with
the study ofKylmälä et al. (8) in which carboxyterminal
cross-linked telopeptide of type I collagen surpassed
prostate-specific antigen as a prognostic indicator for
bone metastases.
In the present study patients were classified in the PC—
group because of normal results obtained from bone
scintigraphy. Because of this, it is hardly surprising that
no pathological median values for the bone quantities
could be detected in comparison with the benign pro-
static hyperplasia control group. However, in the PC-
group, the numbers of elevated values of carboxytermi-
nal propeptide of type I procollagen (but also of amino-
terminal telopeptide of type I collagen) were higher in
comparison with the benign prostatic hyperplasia group,
although these differences did not reach a statistically
significant level. Further longitudinal study is needed in
order to prove if these increases in carboxyterminal pro-
peptide of type I procollagen or aminoterminal telopep-
tide of type I collagen reflect early bone involvement
before the metastasis is visible in routine bone scintigra-
phy or before the other biochemical bone markers are
raised.
In conclusion, biochemical bone markers are signifi-
cantly elevated in patients with prostatic bone metasta-
ses and show a promising diagnostic value for the
detection of osteoblastic or osteoclastic metastatic pro-
cesses.
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